



François GHIRINGHELLI
MD, PhD

Professor, INSERM U866, Cancer Center Georges
Francois Leclerc, DIJON France

François GHIRINGHELLI is an Associate professor of Medical Oncology and research director of an INSERM team working in the field of tumor immunology. His medical training lead him to a degree in medicine in 2006 followed by specialization in clinical oncology. In 2005 he

obtained a PhD in Cellular and Molecular Biology and Immunology in the INSERM Research Unit 517 “Cell death and cancer” directed by Pr. Eric Solary in Dijon.

He discovered the capacity of low dose of cyclophosphamide to electively eliminate regulatory T cells. Subsequently, he obtained a grant from INSERM for a fellowship in Laurence Zitvogel’s laboratory in institute Gustave Roussy. Initially, he worked on regulatory T cells and demonstrated their dependency for expansion at the tumor site on TGF- β production tumor-infiltrating immature dendritic cells. During his postdoctoral fellowship, he conducted research on the direct immuno-enhancing effects of cancer chemotherapy. He contributed to the elucidation of some steps of the mechanism of immunogenic cell death under the direction of Guido Kroemer and Laurence Zitvogel.

Since 2009, he directs a team in Dijon. Currently he pursues research on the effects of cancer chemotherapy on the anti-tumor immune response both in an experimental tumor model in mice and in cancer bearing patients. Notably, he has discovered the capacity of 5-Fluorouracil to eliminate myeloid derived suppressor. He’s also focused on CD4 T cells’ response in tumor bed and on the possibility to improve this anticancer immune response by genetic or pharmacological interventions.